Navigation Links
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
Date:6/8/2009

fective and safe treatment in lowering and/or maintaining normal serum phosphorus levels in patients with ESRD and hyperphosphatemia.

Sales of phosphate binders to treat hyperphosphatemia in ESRD patients in the U.S. were approximately $600 million in 2007, and has grown in excess of 20% per annum over the last five years.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also actively engages in business development activities that include seeking strategic relationships for its product candidates and for the Company, as well as evaluating compounds and companies for in-licensing or acquisition. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for Zerenex and KRX-0401, may be forward-looking statements th
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 The global consumption of squalene / squalane ... a natural skin-identical chemical that finds applications in various end ... pharmaceuticals, and in other applications like high grade lubrication, and ... few major players and is regionally segregated. Sophim ( ... Co. Ltd. ( Japan ), SeaDragon Marine Oils ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. ... processor and marketer of patent protected regenerative biomaterials ... today the publication of another peer-reviewed clinical study.    ... A Multi-center Randomized Controlled Clinical Trial Evaluating the ... Membrane Allografts and Multi-layer Compression Therapy vs. Multi-layer ...
(Date:9/17/2014)... Franklin, MA (PRWEB) September 17, 2014 ... pre-engineered version of its TerraPure tank . This ... tanks is molded from FDA-compliant linear polyethylene and available ... seven pre-installed fittings and ships in two weeks or ... same features and benefits found in Terracon’s existing TerraPure ...
(Date:9/17/2014)... SAN FRANCISCO, Calif. , Sept. 17, 2014 /PRNewswire/ ... ), a molecular diagnostics company pioneering the field of ... Hall to chief operating officer. Mr. Hall ... spearhead the company,s commercial entry into endocrinology. Since 2012, ... operations, as well as managed care and billing functions. ...
Breaking Biology Technology:Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... Collaboration will leverage HUYA,s growing Chinese bioscience network , ... 15 HUYA Bioscience International, a leader in US/China ... subsidiary, N.V. Organon. Schering-Plough has selected HUYA to identify ... lead, preclinical and clinical drug candidates in specific therapeutic ...
... VIENNA, Austria, December 15 bwin, the world,s,leading online ... Health Alliance, a Harvard Medical School Teaching Affiliate, have,just ... The,research objective is to use scientific evidence to create ... of the,world,s largest longitudinal study. , ...
... (Nasdaq: PRXL ), a leading global ... been named the "Best Contract,Research Organization (CRO)" by ... PAREXEL at the fourth annual Scrip Awards ceremony ... Scrip Awards are designed to,celebrate innovation and a ...
Cached Biology Technology:HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China 2HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China 3bwin and Harvard Medical School Faculty Sign 5-Year Research Cooperation Agreement 2PAREXEL Receives Best CRO Award from Scrip 2PAREXEL Receives Best CRO Award from Scrip 3PAREXEL Receives Best CRO Award from Scrip 4
(Date:9/17/2014)... as an EC-FP5 four-year project, delivering its first release ... successful participations in several EC projects, as a part ... project (EU BON), to increase the general awareness of ... the general dissemination of the Fauna Europaea results, the ... its novel e-Publishing tools to prepare data papers for ...
(Date:9/17/2014)... Copenhagen Centre for Social Evolution and Yale University offers ... weight and -length can partially predict the likelihood of ... and schizophrenia later in life. The study analyzed medical ... diagnoses for up to 30 years, and adjusted for ... published today in the Proceedings of the Royal ...
(Date:9/17/2014)... the human retinoblastoma protein gene are a leading cause ... turned to fruit fly eyes to unlock the secrets ... paper featured on the cover of the current issue ... State University researchers provide the first detailed examination of ... the human cancer gene, said Irina Pushel, MSU undergraduate ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Abnormal properties of cancer protein revealed in fly eyes 2
... flamingos are a curiosity of nature. Now a new discovery ... oddity that helps flamingos eat: erectile tissue. , Flamingos are ... water, they bend their necks, tilt their bills upside down ... large tongue acts like a piston, sucking water into the ...
... have interfered with the brain's ability to control an animal's ... published in the latest issue of the Proceedings of the ... is based on the identification of a gene - CPT1c ... According to the researchers, the CPT1c gene protects against weight ...
... neighborhood to a friend's house or deciding on a ... can make decisions based on incomplete information and update ... of such sophisticated decision making in the cerebral cortex, ... studied and little understood," according to Wako Yoshida and ...
Cached Biology News:Ohio University researchers discover evolutionary oddity in flamingos 2Eat less, weigh more? Enzyme makes lean mice 'susceptible' to dietary fat 2Eat less, weigh more? Enzyme makes lean mice 'susceptible' to dietary fat 3Where we change our mind 2
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
Request Info...
LabFax: Immunochemistry...
Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
Biology Products: